MarÃ-a Luisa Lozano

List of Publications by Year
in descending order

146	3,391	172457	175258
papers	citations	29 h-index	52 g-index

159	159	159	4732
all docs	docs citations	times ranked	citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica, 2009, 94, 700-711.	3.5	337
2	Obesity and Inflammation: Change in Adiponectin, C-Reactive Protein, Tumour Necrosis Factor-Alpha and Interleukin-6 After Bariatric Surgery. Obesity Surgery, 2012, 22, 950-955.	2.1	207
3	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	168
4	Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. Journal of Thrombosis and Haemostasis, 2005, 3, 369-376.	3.8	168
5	CCR6 regulates EAE pathogenesis by controlling regulatory CD4⁺ Tâ€cell recruitment to target tissues. European Journal of Immunology, 2009, 39, 1671-1681.	2.9	114
6	Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders. Haematologica, 2018, 103, 148-162.	3.5	96
7	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. British Journal of Haematology, 1997, 99, 304-307.	2.5	92
8	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92
9	Flavonoids inhibit the platelet TxA2signalling pathway and antagonize TxA2receptors (TP) in platelets and smooth muscle cells. British Journal of Clinical Pharmacology, 2007, 64, 133-144.	2.4	76
10	Apigenin Inhibits Platelet Adhesion and Thrombus Formation and Synergizes with Aspirin in the Suppression of the Arachidonic Acid Pathway. Journal of Agricultural and Food Chemistry, 2008, 56, 2970-2976.	5.2	74
11	Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. Blood, 2016, 128, 1282-1289.	1.4	68
12	Towards the targeted management of Chediak-Higashi syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 132.	2.7	57
13	Biallelic Mutations in KDSR Disrupt Ceramide Synthesis and Result in aÂSpectrum of Keratinization Disorders Associated with Thrombocytopenia. Journal of Investigative Dermatology, 2017, 137, 2344-2353.	0.7	53
14	Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfusion and Apheresis Science, 2007, 36, 235-242.	1.0	46
15	Thromboxane A₂Receptor Antagonism by Flavonoids: Structureâ˜Activity Relationships. Journal of Agricultural and Food Chemistry, 2009, 57, 1589-1594.	5.2	46
16	Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets, 2019, 30, 743-751.	2.3	45
17	Differential effects of quercetin, apigenin and genistein on signalling pathways of proteaseâ€activated receptors PAR₁ and PAR₄ in platelets. British Journal of Pharmacology, 2009, 158, 1548-1556.	5.4	44
18	Inherited Platelet Disorders: An Updated Overview. International Journal of Molecular Sciences, 2021, 22, 4521.	4.1	44

#	Article	IF	Citations
19	Design and application of a 23â€gene panel by nextâ€generation sequencing for inherited coagulation bleeding disorders. Haemophilia, 2016, 22, 590-597.	2.1	43
20	Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. British Journal of Haematology, 2001, 115, 969-976.	2.5	38
21	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	3.5	38
22	Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG-CSF for Mobilizing Peripheral Blood Progenitor Cells. British Journal of Haematology, 1997, 96, 418-420.	2.5	34
23	Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia. Journal of Thrombosis and Haemostasis, 2017, 15, 1859-1866.	3.8	34
24	Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder. Blood Advances, 2018, 2, 2341-2346.	5.2	33
25	Migraine and prothrombotic genetic risk factors. Cephalalgia, 1998, 18, 257-260.	3.9	32
26	Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2019, 45, 695-707.	2.7	32
27	An innovative flow cytometric approach for small-size platelet microparticles: Influence of calcium. Thrombosis and Haemostasis, 2012, 108, 373-383.	3.4	31
28	The TFPI 536C â†’T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-788.	3.4	30
29	Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood, 1998, 92, 2771-6.	1.4	30
30	Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study. Orphanet Journal of Rare Diseases, 2014, 9, 213.	2.7	29
31	Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia. Thrombosis and Haemostasis, 2018, 118, 1009-1020.	3.4	29
32	Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion, 1999, 39, 135-143.	1.6	28
33	Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. FÃ¬toterapÃ¬Â¢, 2010, 81, 75-80.	2.2	28
34	Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Scientific Reports, 2021, 11, 7792.	3.3	28
35	Hematologic Î²-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity. Cancer Research, 2012, 72, 4744-4752.	0.9	26
36	Hermansky-Pudlak syndrome. Hamostaseologie, 2014, 34, 301-309.	1.9	26

#	Article	IF	Citations
37	Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis. Platelets, 2018, 29, 192-195.	2.3	26
38	Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfusion Medicine, 2003, 13, 259-266.	1.1	25
39	Immune recovery after autologous or rhGâ€CSF primed PBSC transplantation. European Journal of Haematology, 1996, 56, 301-307.	2.2	25
40	Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: impact of filtration timing. Transfusion, 2000, 40, 781-788.	1.6	23
41	Chediakâ€“<scp>H</scp>igashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. European Journal of Haematology, 2014, 92, 49-58.	2.2	23
42	Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Annals of Hematology, 2016, 95, 1089-1098.	1.8	23
43	New alleles of the platelet glycoprotein Ibα gene. British Journal of Haematology, 1998, 103, 997-1003.	2.5	22
44	CCR6 regulates the function of alloreactive and regulatory CD4+T cells during acute graft-versus-host disease. Leukemia and Lymphoma, 2006, 47, 1469-1476.	1.3	22
45	An early increase of CD56^{bright} natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graftâ€versusâ€host disease. Transfusion, 2018, 58, 2924-2932.	1.6	20
46	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. Thrombosis Research, 2020, 185, 119-124.	1.7	20
47	Rare homozygous status of P43 Î²1-tubulin polymorphism causes alterations in platelet ultrastructure. Thrombosis and Haemostasis, 2011, 105, 855-863.	3.4	19
48	High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease. Blood Coagulation and Fibrinolysis, 2014, 25, 604-611.	1.0	19
49	Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. British Journal of Haematology, 2016, 172, 813-815.	2.5	19
50	Wiskottâ€“Aldrich syndrome in a child presenting with macrothrombocytopenia. Platelets, 2017, 28, 417-420.	2.3	19
51	Down Regulation of the Munc18b-syntaxin-11 Complex and Î²1-tubulin Impairs Secretion and Spreading in Neonatal Platelets. Thrombosis and Haemostasis, 2017, 117, 2079-2091.	3.4	19
52	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. Platelets, 2020, 31, 198-205.	2.3	19
53	Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 651-658.	2.0	18
54	Obesity, endothelial function and inflammation: the effects of weight loss after bariatric surgery. Nutricion Hospitalaria, 2016, 33, 1340-1346.	0.3	18

#	Article	IF	Citations
55	Platelet Cryopreservation Using a Reduced Dimethyl Sulfoxide Concentration and Second-Messenger Effectors as Cryopreserving Solution. Cryobiology, 1999, 39, 1-12.	0.7	17
56	Genotypeâ€“phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. British Journal of Haematology, 2009, 146, 95-103.	2.5	16
57	Influencia de los polimorfismos de CYP2C19 en la reactividad plaquetaria y el pronÃ³stico en una poblaciÃ³n no seleccionada de pacientes con sÃndrome coronario agudo sin elevaciÃ³n del ST. Revista Espanola De Cardiologia, 2012, 65, 219-226.	1.2	16
58	Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of <scp>STAT</scp>3 mutations. British Journal of Haematology, 2016, 172, 937-946.	2.5	16
59	A pilot study on the impact of congenital thrombophilia in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13546.	3.4	16
60	Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients. Thrombosis Research, 2014, 133, 412-417.	1.7	15
61	Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Scientific Reports, 2019, 9, 16680.	3.3	15
62	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVIDâ€19 outcomes. Clinical and Translational Medicine, 2021, 11, e268.	4.0	15
63	Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system. Blood Transfusion, 2012, 10, 480-9.	0.4	15
64	MicroRNAs as potential regulators of platelet function and bleeding diatheses. Platelets, 2019, 30, 803-808.	2.3	14
65	Impaired hemostatic activity of healthy transfused platelets in inherited and acquired platelet disorders: Mechanisms and implications. Science Translational Medicine, 2019, 11, .	12.4	14
66	GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet Journal of Rare Diseases, 2013, 8, 170.	2.7	13
67	The â^'1C>T mutation in the annexin A5gene does not affect plasma levels of annexin A5. Blood, 2003, 101, 4223-4224.	1.4	12
68	RASGRP2 gene variations associated with platelet dysfunction and bleeding. Platelets, 2019, 30, 535-539.	2.3	12
69	Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia. International Journal of Molecular Sciences, 2021, 22, 4330.	4.1	12
70	Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Blood Advances, 2021, 5, 5453-5467.	5.2	12
71	Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells. Bone Marrow Transplantation, 2001, 27, 1287-1292.	2.4	11
72	Evaluation of a new whole-blood filter that allows preparation of platelet concentrates by platelet-rich plasma methods. Transfusion, 2003, 43, 1723-1728.	1.6	11

#	Article	IF	Citations
73	JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. Annals of Hematology, 2008, 87, 763-765.	1.8	11
74	Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing. Annals of Medicine, 2019, 51, 141-148.	3.8	11
75	A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood, 2002, 100, 2081-6.	1.4	11
76	Latent and polymeric antithrombin: clearance and potential thrombotic risk. Experimental Biology and Medicine, 2007, 232, 219-26.	2.4	11
77	Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood, 2022, 140, 140-151.	1.4	11
78	Complejo plaquetario GP Ib/IX/V: papel fisiolÃ³gico. Journal of Physiology and Biochemistry, 2000, 56, 355-365.	3.0	10
79	IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: A case report. Journal of Inherited Metabolic Disease, 2009, 32, 265-267.	3.6	10
80	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	2.2	10
81	Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. International Journal of Molecular Sciences, 2021, 22, 6907.	4.1	10
82	Recomendaciones del Grupo EspaÃ±ol de PTI para el diagnÃ³stico, tratamiento y seguimiento de pacientes con trombocitopenia inmune. Medicina ClÃnica, 2021, 157, 191-198.	0.6	10
83	Resistin in morbidly obese patients before and after gastric bypass surgery. Nutricion Hospitalaria, 2017, 34, 1333-1337.	0.3	10
84	Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Bone Marrow Transplantation, 2000, 25, 231-235.	2.4	9
85	Quality assessment of buffyâ€coatâ€derived leucodepleted platelet concentrates in <scp>PAS</scp>â€plasma, prepared by the <scp>O</scp>rbi<scp>S</scp>ac or <scp>TACSI</scp> automated system. Vox Sanguinis, 2014, 106, 38-44.	1.5	9
86	Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells. Annals of Hematology, 1995, 71, 105-110.	1.8	8
87	In Vitro Changes of Platelet Parameters: Lessons From Blood Banking. , 2004, 273, 057-072.		8
88	Generation of induced pluripotent stem cells (iPSCs) from a Bernardâ€“Soulier syndrome patient carrying a W71R mutation in the GPIX gene. Stem Cell Research, 2016, 16, 692-695.	0.7	8
89	Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?. Platelets, 2020, 31, 906-912.	2.3	8
90	Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study. Blood, 2019, 134, 2361-2361.	1.4	8

#	Article	IF	Citations
91	Evaluation of refrigerated platelet concentrates supplemented with low doses of second messenger effectors. International Journal of Laboratory Hematology, 2004, 26, 275-286.	0.2	7
92	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. Aids, 2016, 30, 1141-1142.	2.2	7
93	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	3.5	7
94	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. Thrombosis and Haemostasis, 2008, 100, 1211-1213.	3.4	6
95	Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2012, 65, 219-226.	0.6	6
96	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clinical Case Reports (discontinued), 2017, 5, 1887-1890.	0.5	6
97	Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia. Lancet Haematology,the, 2022, 9, e168-e169.	4.6	6
98	Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients. Cancers, 2022, 14, 3106.	3.7	6
99	Comparative Study of Three Methods to Detect Free Plasma Antiplatelet Antibodies. Acta Haematologica, 1996, 96, 135-139.	1.4	5
100	An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets. Thrombosis and Haemostasis, 2015, 114, 313-324.	3.4	5
101	Efecto de la administraciÃ³n precoz de pravastatina en los valores de proteÃna C reactiva y de interleucina 6 en la fase aguda del infarto de miocardio con elevaciÃ³n del segmento ST. Revista Espanola De Cardiologia, 2004, 57, 916-923.	1.2	5
102	Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease. Blood, 2019, 134, 4466-4466.	1.4	5
103	Bone marrow steady-state CD34+/CD71â˜ cell content is a predictive value of rG-CSF-mobilized CD34+ cells. Bone Marrow Transplantation, 1998, 21, 983-985.	2.4	4
104	In vitro analysis of platelet concentrates stored in the presence of modulators of 3â€²,5â€² adenosine monophosphate, and organic anions. Transfusion Science, 2000, 22, 3-11.	0.6	4
105	Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies. Haematologica, 2008, 93, 1436-1438.	3.5	4
106	Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy. Scientific Reports, 2017, 7, 44556.	3.3	4
107	GENYOi005-A: An induced pluripotent stem cells (iPSCs) line generated from a patient with Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) carrying a p.Thr196Ala variant. Stem Cell Research, 2019, 41, 101603.	0.7	4
108	A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. Blood Cells, Molecules, and Diseases, 2021, 86, 102505.	1.4	4

#	Article	IF	Citations
109	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	4
110	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. Thrombosis and Haemostasis, 2008, 100, 1211-3.	3.4	4
111	Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. Blood Coagulation and Fibrinolysis, 2002, 13, 95-103.	1.0	3
112	Evaluation of twoâ€step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites. Vox Sanguinis, 2014, 107, 343-350.	1.5	3
113	The TFPI 536C-->T mutation is not associated with increased risk for venous or arterial thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-8.	3.4	3
114	Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease. Blood Advances, 2022, 6, 5244-5255.	5.2	3
115	A Radioreceptor Assay for Mass Measurement of Inositol (1,4,5)-Trisphosphate Using Saponin-Permeabilized Outdated Human Platelets. Analytical Biochemistry, 1998, 256, 117-121.	2.4	2
116	Evaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 inGNB3.		

#	Article	IF	Citations
127	Induced pluripotent stem cells derived from Bernard-Soulier Syndrome patient's peripheral blood cells with a p.Phe55Ser mutation in the GPIX gene. Stem Cell Research, 2017, 20, 10-13.	0.7	1
128	Performance and usefulness of platelet aggregation testing. Platelets, 2018, 29, 637-637.	2.3	1
129	Trasplante de progenitores hematopoyÃ©ticos de sangre perifÃ©rica en EspaÃ±a: anÃ¡lisis de coste. Medicina ClÃnica, 2004, 123, 401-405.	0.6	1
130	Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study. Blood, 2019, 134, 1088-1088.	1.4	1
131	Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up. Blood, 2019, 134, 2370-2370.	1.4	1
132	Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors. Transfusion, 2004, 44, 1755-1761.	1.6	0
133	Does the Holy Grail escape us again?. European Heart Journal, 2009, 30, 1152-1152.	2.2	0
134	Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematology, 2018, 23, 712-718.	1.5	0
135	Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project. Molecular Genetics and Metabolism, 2019, 126, S22-S23.	1.1	0
136	Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia. Medicina ClÃnica (English Edition), 2021, 157, 191-198.	0.2	0
137	Impact of Constitutional Polymorphisms in VCAM1, CD44, CXCL12, CXCR4 and CSF3R in Progenitor Cell Mobilization in Patients with Hematological Malignancies. Blood, 2011, 118, 2997-2997.	1.4	0
138	Deubiquitnase BAP1 Downregulation in Myeloid Malignances: A New Pathogenic Mechanism, Dominant in Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 5594-5594.	1.4	0
139	Persistent Cytotoxic T Lymphocyte Expansions after Allogeneic Hematopoietic Stem Cell Transplantation: Kinetics, Clinical Impact and Absence of STAT3 Mutations. Blood, 2015, 126, 3153-3153.	1.4	0
140	Multicentric, Retrospective Study of Extracorporeal Photopheresis, Off-Line System, in Corticosteroid Refractory Acute and Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 3405-3405.	1.4	0
141	Ten New Cases of Hermansky-Pudlak Syndrome in the Iberian Peninsula: Identification of Novel Genetic Variants in HPS3, HPS4, HPS6 and DTNBP1 Associated with Significant Clinical Complications. Blood, 2018, 132, 1147-1147.	1.4	0
142	Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project. Blood, 2018, 132, 4942-4942.	1.4	0
143	Strategies for Analysis of Novel Molecular Variants in the RUNX1 Gene As a Cause of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML). Blood, 2019, 134, 2359-2359.	1.4	0
144	A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding. Blood, 2019, 134, 2375-2375.	1.4	0

#	Article	IF	Citations
145	Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 136-140.	0.3	0
146	Respuesta. Medicina ClÃnica, 2021, 158, e2-e2.	0.6	0